Goldman Sachs Group Inc. Has $1.30 Million Stock Position in Savara Inc. $SVRA

Key Points

• Goldman Sachs reduced its stake in Savara Inc. by 29.8%, owning approximately 0.27% of the company worth $1.3 million after selling nearly 199,000 shares in the first quarter.
• Institutional investors and hedge funds collectively own 87.93% of Savara's stock, indicating strong institutional support for the company.
• Savara recently faced a missed earnings expectation for the last quarter, reporting an EPS of -$0.14 against the consensus estimate of -$0.12.

Goldman Sachs Group Inc. lowered its stake in Savara Inc. (NASDAQ:SVRA - Free Report) by 29.8% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 467,547 shares of the company's stock after selling 198,935 shares during the period. Goldman Sachs Group Inc. owned approximately 0.27% of Savara worth $1,295,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Bain Capital Life Sciences Investors LLC grew its stake in Savara by 20.8% in the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company's stock valued at $48,754,000 after buying an additional 3,035,164 shares during the last quarter. Frazier Life Sciences Management L.P. grew its position in shares of Savara by 32.4% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company's stock worth $31,751,000 after purchasing an additional 2,801,922 shares in the last quarter. Vestal Point Capital LP grew its position in shares of Savara by 2.1% during the 1st quarter. Vestal Point Capital LP now owns 11,000,000 shares of the company's stock worth $30,470,000 after purchasing an additional 225,000 shares in the last quarter. Nantahala Capital Management LLC grew its position in shares of Savara by 7.3% during the 1st quarter. Nantahala Capital Management LLC now owns 8,075,375 shares of the company's stock worth $22,369,000 after purchasing an additional 550,116 shares in the last quarter. Finally, Emerald Advisers LLC grew its position in shares of Savara by 32.5% during the 1st quarter. Emerald Advisers LLC now owns 3,090,213 shares of the company's stock worth $8,560,000 after purchasing an additional 757,533 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Wells Fargo & Company decreased their target price on shares of Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 28th. Guggenheim increased their target price on shares of Savara from $8.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday, September 9th. Oppenheimer increased their target price on shares of Savara from $6.00 to $8.00 and gave the stock an "outperform" rating in a research report on Monday, September 8th. HC Wainwright increased their target price on shares of Savara from $5.00 to $8.00 and gave the stock a "buy" rating in a research report on Wednesday, September 3rd. Finally, Evercore ISI reduced their price target on shares of Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a research report on Wednesday, May 28th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $7.50.

Savara Stock Down 1.9%

SVRA opened at $3.53 on Friday. The firm has a market capitalization of $610.13 million, a P/E ratio of -7.06 and a beta of 0.56. The company has a debt-to-equity ratio of 0.25, a current ratio of 11.08 and a quick ratio of 11.08. Savara Inc. has a fifty-two week low of $1.89 and a fifty-two week high of $4.70. The company's 50-day moving average is $3.00 and its 200 day moving average is $2.79.

Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Research analysts expect that Savara Inc. will post -0.45 earnings per share for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc. (NASDAQ:SVRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.